This is not a paywall.

Register for free to continue reading.

We made a promise to you that we’ll never erect a paywall and we intend to keep that promise. We also want to continually improve your reading experience and you can help us do that by registering with us. It’s quick, easy and will cost you nothing.

Nearly there! Create a password to finish up registering with us:

Please enter your password or get a login link if you’ve forgotten

Open Sesame! Thanks for registering.

First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Covid Pill Birth Defect Risk Sinks Pharma Stock by Most...

Business Maverick

Business Maverick

Covid Pill Birth Defect Risk Sinks Pharma Stock by Most in Decade

Customers look at products displayed at a pharmacy in Sendai, Miyagi Prefecture, Japan, on Friday, May 15, 2020. Photographer: Soichiro Koriyama/Bloomberg
By Bloomberg
13 Apr 2022 0

Shionogi & Co slumped the most in more than a decade after the pharmaceutical company said animal studies showed its experimental Covid drug disturbed foetal development. 

The stock fell as much as 16% in Tokyo trading Wednesday, the biggest intraday decline since March 2011. The stock had been down 8.4% this year through yesterday.

The drug likely won’t be recommended for pregnant women, Kyodo News reported Tuesday, without giving attribution. The animal data, which showed harm when it was given at high doses, was submitted to Japanese regulators in February when the company sought a review, a Shionogi spokesman said.

The pill’s chances of success fell to 5% from 50% after the report tying it to birth defects, Stephen Baker, an equities analyst at Jefferies & Co., wrote in a note to clients. He cut his rating on the stock to “underperform” from “buy” on Wednesday after trimming the profit estimates and target price.

Still, rival Covid treatments also carry risks for pregnant women but have been approved for use. Merck & Co.’s Lagevrio has a boxed warning saying it shouldn’t be taken by pregnant women after it was linked to fetal harm in animal studies. Pfizer Inc.’s Paxlovid at high doses led to a decrease in fetal body weight in a rabbit study, though there aren’t restrictions on its use during pregnancy.

The possibility of birth defects isn’t new and shouldn’t affect approval, said Naomi Kumagai, an equities analyst at Mitsubishi UFJ Morgan Stanley Securities Co. in a note to clients. Reports by Japanese media are misleading, she said.

“Generally, it’s rare for regulators to recommend drugs to pregnant women aggressively,” said Kumagai. “It’s normal to ban drugs or take in benefits and risks into account for the group. Other Covid drugs have similar risks too.”

Approval of Shiongi’s drug would give Japan, one of the world’s oldest nations, an indigenous supply of antiviral medication for Covid as it slowly eases social restrictions, reopens its economy and works to better control the disease in future outbreaks. Demand for drugs to treat Covid is fierce as the world transitions to an endemic state and the focus shifts to the need for easy-to-take medications.

Rival Medicines

Pfizer’s Paxlovid was authorized to treat mild and moderate symptoms of Covid-19 in Japan in February, while Merck’s Lagevrio was cleared for use in December. The government signed contracts to purchase Merck’s pill for 1.5 million people, and Pfizer’s drug for 2 million people.

Use of the drugs hasn’t been widely studied during human pregnancy, so little information is available on major birth defects, miscarriage, or adverse outcomes for mothers or the infants.

Shionogi’s pill is a protease inhibitor that works like Pfizer’s Paxlovid. The drugs target a different part of the virus replication process than Merck’s medicine. It’s possible the Shionogi drug could be given in combination with Merck’s treatment, something the companies have discussed, Chief Executive Officer Isao Teshirogi said in October.

The drug has the potential to generate $2 billion in annual sales, Teshirogi has said. The company partnered with the AIDS Clinical Trial Group in March to run studies needed to get U.S. approval.

Read more: Covid Pill Sales Could Hit $2 Billion, Japan’s Shionogi Says

Shionogi previously said it would have enough medicine for 1 million people by end of March. It plans to eventually produce enough to treat 10 million people annually. Japan’s government agreed in March to buy 1 million courses of the antiviral drug immediately after approval. BM


Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

No Comments, yet

Please peer review 3 community comments before your comment can be posted